Cure8 research brief
Why This Matters
A cross‑trust histopathology MDT helped reclassify diagnoses in a substantial proportion of discussed paediatric IBD cases and occasionally changed management or transition planning, which could affect treatment decisions for adolescents with diagnostic uncertainty.
Who Should Pay Attention
Pediatric IBD clinicians, pathologists, transition coordinators, and families of adolescents with IBD‑unclassified or complex disease.
Study Snapshot
What To Know
This report describes a retrospective review of eight Cross‑Trust histopathology multidisciplinary team (MDT) meetings (Jan 2021–Mar 2024) focused on complex paediatric IBD cases and transition to adult services. Twenty‑seven adolescents/young adults (mean age 17.2) were discussed.
The MDT led to a change in diagnosis for 11 patients (41%), including reclassifying IBD‑unclassified to ulcerative colitis or Crohn’s disease, and one non‑IBD reclassification. Management recommendations changed in 3 patients (11%), and one patient had a transition pathway modification.
The authors note that MDT outputs were rarely uploaded to the paediatric electronic health record (3 cases, 11%), highlighting documentation gaps.
Keep In Mind
Single‑centre retrospective series with a small sample size and abstract‑level reporting; results describe diagnostic and process impacts rather than measured long‑term patient outcomes.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.